Pharsight

Lysteda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9060939 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US7947739 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US8022106 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US8273795 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US8487005 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US8791160 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US8957113 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

US8809394 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(1 year, 5 months from now)

Lysteda is owned by Amring Pharms.

Lysteda contains Tranexamic Acid.

Lysteda has a total of 8 drug patents out of which 0 drug patents have expired.

Lysteda was authorised for market use on 13 November, 2009.

Lysteda is available in tablet;oral dosage forms.

Lysteda can be used as treatment of cyclic heavy menstrual bleeding.

The generics of Lysteda are possible to be released after 04 March, 2025.

Drugs and Companies using TRANEXAMIC ACID ingredient

Market Authorisation Date: 13 November, 2009

Treatment: Treatment of cyclic heavy menstrual bleeding

Dosage: TABLET;ORAL

How can I launch a generic of LYSTEDA before it's drug patent expiration?
More Information on Dosage

LYSTEDA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic